LA JOLLA PHARMACEUTICAL CO·4

May 28, 3:38 PM ET

SLOAN GAIL A 4

4 · LA JOLLA PHARMACEUTICAL CO · Filed May 28, 2010

Insider Transaction Report

Form 4
Period: 2010-05-26
SLOAN GAIL A
VP of Finance
Transactions
  • Award

    Common Stock

    2010-05-26$0.03/sh+94,038$2,82194,038 total
  • Award

    Series C-2 Convertible Pfd Stock Warrants (right to buy)

    2010-05-26+4444 total
    Exercise: $1000.00From: 2010-05-26Exp: 2013-05-26Series C-2 Convertible Preferred Stock (44 underlying)
  • Award

    Series C-1 Convertible Preferred Stock

    2010-05-26$1000.00/sh+22$22,00022 total
    Exercise: $0.01From: 2010-12-03Common Stock (1,466,674 underlying)
  • Award

    Series D-1 Convertible Pfd Stock Warrants (right to buy)

    2010-05-26+2222 total
    Exercise: $1000.00From: 2010-05-26Exp: 2013-05-26Series D-1 Convertible Preferred Stock (22 underlying)
Footnotes (3)
  • [F1]The Series C-1 Convertible Preferred Stock (the "Series C-1 Stock") is initially convertible into shares of common stock of La Jolla Pharmaceutical Company at a price per share of $0.015, but such conversion price will be adjusted for certain events, such as stock splits, stock dividends, reclassifications and recapitalizations, and is subject to full-ratchet anti-dilution protection such that any subsequent issuance of common stock below $0.015 automatically adjusts the conversion price of the Series C-1 Stock to such lower price.
  • [F2]The Series C-1 Stock does not have a set expiration date, although the holders of such stock may require the Company to redeem the Series C-1 Stock upon certain events.
  • [F3]Upon exercise of these Series C-2 Convertible Preferred Stock Warrants, Ms. Sloan will receive up to 44 shares of Series C-2 Convertible Preferred Stock and warrants to purchase up to 44 shares of Series D-2 Convertible Preferred Stock.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION